Loss of MicroRNA Decoy Might Contribute to Development of Soft-Tissue Sarcoma
News Aug 08, 2013
Researchers have discovered a novel mechanism responsible for the loss of a critical tumor-suppressor gene in rhabdomyosarcoma and other soft-tissue sarcomas, rare cancers that strike mainly children and often respond poorly to treatment. Their cause is largely unknown.
Knowledge of the mechanism could guide the development of more effective therapies for these malignancies, say researchers who led the study at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
The researchers found that the tumor-suppressor gene called A20 is silenced not by mutation, as in many other cancers, but because a second molecule is lost, a small molecule called microRNA-29 (miR-29). In addition, they found that miR-29 normally protects A20 from destruction. When miR-29 is absent, A20 is degraded. Loss of A20, in turn, leads to a dramatic rise in levels of a protein called NF-kB and to tumor progression.
The findings are published in the journal Science Signaling.
“We do know that NF-kB is a tumor promoter, but we don't know why it is upregulated in many cancers,” says principal investigator Denis Guttridge, PhD, professor of molecular virology, immunology and medical genetics and a member of the OSUCCC – James Molecular Biology and Cancer Genetics Program.
“Our study indicates that it involves a regulatory circuit between NF-kB, miR-29 and the A20 tumor-suppressor gene,” Guttridge says. “It also identifies NF-kB as a therapeutic target in sarcoma and A20 and miR-29 as potential biomarkers for sarcoma.”
“We are excited about these findings because they open up new vistas on the role of microRNAs in sarcoma development and provide a rationale for further interrogating this circuitry as a potential target for new treatments,” says study pathologist and coauthor O. Hans Iwenofu, MD, FCAP, assistant professor of pathology and member of the OSUCCC – James Molecular Biology and Cancer Genetics Program.
Soft-tissue sarcomas – cancers of muscle, other soft tissues and bone – make up about 15 percent of pediatric cancer cases. In 2013, about 11,400 cases of sarcoma are expected in the United States, and about 4,400 Americans are expected to die from the malignancy.
For this study, Guttridge, Iwenofu and their colleagues used human tumor samples, cell lines and animal models. Key technical findings include:
• miR-29 and A20 expression are abnormally low in sarcomas;
• The A20 gene showed little evidence of mutation;
• Restoring miR-29 levels in sarcoma cells caused A20 levels to rise;
• miR-29 normally binds with a protein called HuR; when miR-29 is absent, HuR binds with A20, leading to the degradation of A20;
• When miR-29 binds with HuR, it acts as a decoy and protects A20 from HuR-mediated degradation.
“The loss of the A20 tumor-suppressor gene because the microRNA decoy is absent may represent another mechanism to explain why NF-kB is constitutively active in sarcoma cancers,” Guttridge says.
Funding from the NIH/National Cancer Institute (grants CA163995-01, CA143082) and a Pelotonia fellowship supported this research.
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
RNA Molecules Lives Are 10 Times Shorter Than Previously ThoughtNews
A research group at the Biozentrum of the University of Basel has developed a new method to measure the half-life of RNA molecules.READ MORE
Changing microRNA's Presence in Glioblastoma Cells Could Change the Tumor's SubtypeNews
BWH researchers examined a specific microRNA, miR-128, to help identify glioblastoma subtypes and to determine if altering the microRNA's presence in glioblastoma cells could change the tumor's subtype.READ MORE
Comments | 0 ADD COMMENT
International Conference on Genomics and Pharmacogenomics
Jul 18 - Jul 19, 2018
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018